Diagnostic imaging and therapeutic agents to help identify and treat disease and improve patient care
Improved diagnostic information for better patient management
Lantheus Appoints Vivian Yao as Chief Human Resources Officer
Lantheus Announces PYLARIFY AI™ is Now Available
Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022
Providing you with important information regarding our response to the C0VID-19 pandemic.
View a Lantheus webinar:
COVID-19: Clinical Experiences from the Front Line in NYC
Lantheus Appoints Vivian Yao as Chief Human Resources Officer
Lantheus Announces PYLARIFY AI™ is Now Available
Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022
At Lantheus, we develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.
We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.